Utilizing Bayesian Analysis To Make Go/No-Go Decisions In A Platform Trial

In recent years, platform clinical trials have gained substantial support and provide an efficient way of testing multiple compounds in a single and consistent framework. In the traditional setting, each new compound requires independent proof-of-concept, phase 2A and 2B trials to be designed and conducted. In this setting patients are often randomized between the new treatment and control, with the same control utilized in many studies. In contrast, platform clinical trials utilize a master protocol with each new compound added through an intervention specific appendix. This innovative approach leverages the common control, patient outcomes and recruitment centers to improve efficiency in terms of operations, analysis and decision making. In this presentation we review platform trials including terminology, protocol structure overview and discuss some of the key advantages. We also share a concept for a platform trial that utilizes Bayesian modeling to make Go/No-Go decisions and discuss the potential benefits and risks of a platform trial.